Bio Medica Laboratories Ltd IPO
Status: Closed
Overview
IPO date
21 May 2026 to 25 May 2026
Face value
âč 10 per share
Price
âč 132 to âč139 per share
Issue Size
3,772,000 shares
(aggregating up to âč 52.43 Cr)
(aggregating up to âč 52.43 Cr)
Allotment Date
26 May 2026
Listing at
NSE
Issue type
Book Building - SME
Sector
Pharmaceuticals
Unlock Stock of the Month
T&C*
Strengths vs Risks of Bio Medica Laboratories Ltd
Know the pros & cons
Strengths
- Designing and execution capabilities.
- Experienced management team and a motivated and efficient work force.
- Cordial relations with our consumers.
- Quality assurance and control.
Risks
- The operations in the company Manufacturing Unit-1 had been suspended vide order No. V/T/MISC/20/2023/4790 dated August 23, 2023 by the Deputy Director and State Licensing Authority, Food and Drug Administration, Madhya Pradesh citing certain non-compliances.
- The company is dependent on a limited number of clients for a significant portion of its revenues, and the loss of any key client could adversely affect the company business, financial condition and results of operations.
- Any manufacturing or quality control problems may damage the company reputation for high quality products and expose its to litigation or other liabilities, which could adversely affect the company financial results.
- The Company's manufacturing facilities are subject to inspections by the Central Drugs Standard Control Organisation (CDSCO), the State Licensing Authorities, and other competent regulatory bodies. Any adverse findings or non-compliance may result in regulatory actions that could adversely affect the Company's business, operations, and financial performance
- The company is dependent on third-party transportation providers for the supply of raw materials and finished products
- The company inability to adopt new technologies could adversely affect its business, results of operations, cash flows and financial condition.
- The Contracts in the company order book may be adjusted, cancelled, or suspended by its clients at their discretion, and therefore the company order book is not necessarily indicative of future revenues or earnings.
- The company existing manufacturing facilities are concentrated in a single region i.e., Industrial Area, Indore, Madhya Pradesh and the inability to operates and grow its business in this particular region may have an adverse effect on the company business, financial condition, results of operations, cash flows and future business prospects.
- The Company has negative cash flows from its investment and financing activities in the current and past years. Sustained negative cash flow could have an impact on the company growth and business.
- The Company has had a high debt-to-equity ratio in previous financial years, and although this has improved in FY 2025, there can be no assurance that its will be able to maintain such levels going forward, which may affect the company ability to meet obligations and pursue growth opportunities.
- The Company does not own the premises through which its conduct the company business operations.
- The risks associated with delays in obtaining, or failure to obtain, approvals and permits for the building plan of the company proposed manufacturing facility.
- The Company is yet to place orders for all the plant & machineries for its proposed object, as specified in the Objects of the Issue. Any delay in placing orders, procurement of plant & machineries may delay the company implementation schedule and may also lead to increase in price of these plant & machineries, further affecting its revenue and profitability.
- There is outstanding legal proceedings involving the company Promoters and Directors. Any adverse decision in such proceedings may have a material adverse effect on its business, results of operations and financial condition.
- The company contingent liabilities as stated in its Restated Financial Statements could adversely affect the company financial conditions.
- The company Group Company have incurred losses during the last three financial years.
- The Company may not has complied with certain statutory provisions of the Companies Act, 2013. Such non- compliances / lapses may attract penalties and prosecution against the Company and its directors which could impact on the financial position of the Company to that extent.
- If any of the company products cause or is perceived to cause, side effects, the company business, results of operations and financial condition could be adversely affected.
- The company insurance coverage in connection with its business may not be adequate and may adversely affect the company operations and profitability.
- The Company operates under several statutory and regulatory permits, licenses and approvals. Its failures to obtain and/or renew any approvals or licenses in future may have an adverse impact on the company business operations.
- The Company has made certain delayed filings with respect to provisions of the GST Act, Income Tax Act, and other applicable laws in the last 5 Years.
- The Company's operations and descisions is subject to lender's strict covenants and conditions
- The Company operates under several statutory and regulatory permits, licenses and approvals. Its failures to obtain and/or renew any approvals or licenses in future may have an adverse impact on the company business operations.
- If the company fail to maintain an effective system of internal controls, its may not be able to successfully manage or accurately report the company financial risk.
- The average cost of acquisition of Equity Shares by the company Promoter could be lower than the Issue Price.
- The interests of the company Promoters and Directors may cause conflicts of interest in the ordinary course of its business.
- The company could be harmed by employee misconduct or errors that are difficult to detect and any such incidences could adversely affect its financial condition, results of operations and reputation.
- The Offer for Sale proceeds not to be available to the Company
- The Company has obtained unsecured loans amounting to Rs. 1,147.17 Lakhs on the basis of restated consolidated financial statements that may be recalled by the lenders at any time.
- The company is dependent on suppliers of raw materials required for its manufacturing operations. Absence of long-term contracts or agreements with suppliers could adversely affect the company business, financial condition and results of operations.
- Changes in laws applicable regulations governing the import of raw materials may adversely affect the company business, financial condition, and results of operations
- Risk from of data leaks in the last three years and its impact.
- Foreign currency exposure and exchange rate fluctuations between the Indian Rupee and foreign currencies
- The company business and operation is subject to extensive regulation in India, and any adverse changes in regulatory framework may affect its Business and operations.
- The risk of theft, accidents at the plant and goods in transit
- The Company has entered into certain related party transactions in the past and may continue to does so in the future.
- The company business relies on skilled personnel, and its inability to recruit and retain such personnel could adversely impact the company operations and growth prospects
- The company is dependent on its Promoters, the company senior management and other key personnel, and the loss of, or its inability to attract or retain, such persons could affect the company business, results of operations, financial condition and cash flows.
- If its fail to maintain an effective system of internal controls, the company may not be able to successfully manage or accurately report its financial risk.
- Some of the company's Board of Directors does not has experience of listed companies.
- The interests of the company Promoters and Directors may cause conflicts of interest in the ordinary course of its business.
- The company could be harmed by employee misconduct or errors that is difficult to detect and any such incidences could adversely affect its financial condition, results of operations and reputation.
- The company faces competition in its business from organized and unorganized players, which may adversely affect the company business operation and financial condition.
- Information relating to the installed manufacturing capacity, actual production and capacity utilization of the company manufacturing units included in this Red Herring Prospectus is based on various assumptions and estimates, and future production and capacity may vary.
- The company inability to manage growth could disrupt its business and reduces profitability.
- The Company's future funding requirements, in the form of further issue of capital or other securities and/or loans that might be availed by its, may turn out to be prejudicial to the interest of the shareholders depending upon the terms and conditions on which they are raised.
- In addition to normal remuneration or benefits and reimbursement of expenses, some of the company Promoters and Directors are interested in its Company to the extent of their shareholding and dividend entitlement in the Company.
- The company ability to pay dividends in the future will depends on its earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of the company financing arrangements.
- Certain key performance indicators for certain listed industry peers included in this Red Herring Prospectus has been sourced from public sources and there is no assurance that such financial and other industry information is complete.
- This Red Herring Prospectus contains information from third parties, including an industry report prepared by an independent third-party research agency, Infomerics Analytics and Research Private Limited, which the company has commissioned and paid for purposes of confirming its understanding of the industry exclusively in connection with the Offer.
- The company will continue to be controlled by its Promoter and Promoter Group after the completion of the Issue, which will allow them to influence the outcome of matters submitted for approval of the company shareholders.
- There is certain restrictions on daily movements in the price of Equity Shares, which may adversely affect a shareholder's ability to sell, or the price at which it can sell, Equity Shares at a particular point in time.
- After this Issue, the price of the Equity Shares may be highly volatile, or an active trading market for the Equity Shares may not develop.
- Market price of the company share will be decided by market forces and issue price of equity share may not be indicative of the market price its share price after the issue.
- Rights of shareholders under Indian law may be more limited than under the laws of other jurisdictions.
- Any variation in the utilization of the Net Proceeds as disclosed in this Draft Red Herring Prospectus shall be subject to certain compliance requirements, including prior approval of the shareholders of the Company.
- Equity Shares of the Company has never been publicly traded, and after the Issue, the Equity Shares may be subject to price and volume fluctuations, and an active trading market for the Equity Shares may or may not develop. Further, the Issue Price may not be indicative of the market price of the Equity Shares after the Issue.
- Investors will not be able to sell immediately on an Indian stock exchange any of the Equity Shares they purchase in the Issue.
- Holders of Equity Shares may be restricted in their ability to exercise pre-emptive rights under Indian law and thereby may suffer future dilution of their ownership position.
- A third-party could be prevented from acquiring control of the company post this Issue, because of anti-takeover provisions under Indian law.
- QIB and Non-Institutional Investors is not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid.
Bio Medica Laboratories Ltd Peer Comparison
Understand the companyâs industry standing
Bio Medica Laboratories Ltd
Zenotech Laboratories Limited
Shukra Pharmaceuticals Limited
Face Value
10
10
1
Standalone / Consolidated
Standalone
Standalone
Standalone
Total Income Rs. Cr.
---
---
---
EPS-Basis
10.67
0.92
0.22
EPS-Diluted
10.67
0.92
0.22
NAV Per Share
16.05
15.76
1.43
P/E-Basic EPS
---
---
47.57
P/E-Diluted EPS
---
---
---
RONW(%)
99.59
6.01
15.9
Latest NAV Period
---
---
---
Latest NAV
---
---
---
How to check the allotment status of Bio Medica Laboratories Ltd IPO?
Follow the steps
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
Select company from dropdown menu.
Enter details- PAN, Application number or DP client ID
Get your allotment status
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
IPO reads
Stay updated with the latest IPO developments
February 27, 2025 | 5 min read
âč50.11 Cr Balaji Phosphates IPO Opens Feb 28. Issue Details and SWOT AnalysisRead More
February 25, 2025 | 5 min read
Tata Capital Board Approves âč15,000 Cr Plus Mega IPO; Tata Investment Shares Soar 8%Read More
February 18, 2025 | 5 min read
Busy Week Ahead: 2 SME IPOs and 9 Market Listings â Get the Complete Details HereRead More
October 25, 2024 | 5 min read
Waaree Energies IPO: GMP Soars 106% Amid 76.34x Subscription â Check Your Allotment Status!Read More
October 22, 2024 | 5 min read
Upcoming IPOs: 9 Public Issues Set to Raise âč10,984.8 Cr â Key Insights Inside!Read More
October 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
September 6, 2024 | 5 min read
Bajaj Housing Finance IPO: All You Need to KnowRead MoreOctober 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
August 26, 2024 | 5 min read
Premier Energies IPO: Key Details Ahead of the âč2,830.40 Cr Issue LaunchRead MoreMore on IPOs
Navigate your way to other IPO resources
Latest videos on IPOs
IPO highlights & details!
FAQs on IPO
Get answers to all your questions here!
The IPO opens on 21 May 2026 & closes on 25 May 2026.
Bio Medica Laboratories Limited was originally incorporated as a private limited Company with the name of 'Bio Medica Laboratories Private Limited' vide certificate of Incorporation dated August 14, 2015, issued by Registrar of Companies, Gwalior. Further, the status got converted into a Public Company & name of the Company changed from 'Bio Medica Laboratories Private Limited' to 'Bio Medica Laboratories Limited' & Registrar of Companies, CPC has issued a new Certificate of Incorporation dated October 24, 2024.
Company is engaged in the of manufacturing of Pharmaceutical Parenteral Formulations. It manufacture variety of products, comprising ethical drugs, generic drugs and over the-counter drugs (OTC) in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs.
Company operates on a B2B business model through contract manufacturing and does not deal directly with the end users. It manufacture formulations for various companies according to their specific requirements and specifications for the type of formulation needed. Additionally, it enter into agreements with them, allowing their name and address to be displayed on the packaging as 'Technical Collaborator' or 'marketed by' alongside the Company's name as the manufacturer.
Company is planning the public issue by issuing an aggregate of 37,71,600 equity shares of face value Rs 10 each, comprising a fresh issue of 33,94,800 equity shares and 3,76,800 equity shares through offer for sale.
Bio Medica Laboratories Ltd IPO will close on 25 May 2026.
- Designing and execution capabilities.
- Experienced management team and a motivated and efficient work force.
- Cordial relations with our consumers.
- Quality assurance and control.
| S.No | Promoters Name | Pre Issue Shares | Pre Issue Percentage | Post Issue Shares | Post Issue Percentage |
|---|---|---|---|---|---|
| 1 | Mukesh Mehta | 4444816 | 48.42 | 4256316 | 33.85 |
| 2 | Pradeep Mehta | 4444725 | 48.42 | 4256225 | 33.85 |
| 3 | Tara Mehta | 92 | --- | 92 | --- |
| 4 | Lokesh Jain | 92 | --- | 92 | --- |
| 5 | Garima Mehta | 92 | --- | 92 | --- |
| 6 | Anju Mehta | 92 | --- | 92 | --- |
- The operations in the company Manufacturing Unit-1 had been suspended vide order No. V/T/MISC/20/2023/4790 dated August 23, 2023 by the Deputy Director and State Licensing Authority, Food and Drug Administration, Madhya Pradesh citing certain non-compliances.
- The company is dependent on a limited number of clients for a significant portion of its revenues, and the loss of any key client could adversely affect the company business, financial condition and results of operations.
- Any manufacturing or quality control problems may damage the company reputation for high quality products and expose its to litigation or other liabilities, which could adversely affect the company financial results.
- The Company's manufacturing facilities are subject to inspections by the Central Drugs Standard Control Organisation (CDSCO), the State Licensing Authorities, and other competent regulatory bodies. Any adverse findings or non-compliance may result in regulatory actions that could adversely affect the Company's business, operations, and financial performance
- The company is dependent on third-party transportation providers for the supply of raw materials and finished products
- The company inability to adopt new technologies could adversely affect its business, results of operations, cash flows and financial condition.
- The Contracts in the company order book may be adjusted, cancelled, or suspended by its clients at their discretion, and therefore the company order book is not necessarily indicative of future revenues or earnings.
- The company existing manufacturing facilities are concentrated in a single region i.e., Industrial Area, Indore, Madhya Pradesh and the inability to operates and grow its business in this particular region may have an adverse effect on the company business, financial condition, results of operations, cash flows and future business prospects.
- The Company has negative cash flows from its investment and financing activities in the current and past years. Sustained negative cash flow could have an impact on the company growth and business.
- The Company has had a high debt-to-equity ratio in previous financial years, and although this has improved in FY 2025, there can be no assurance that its will be able to maintain such levels going forward, which may affect the company ability to meet obligations and pursue growth opportunities.
- The Company does not own the premises through which its conduct the company business operations.
- The risks associated with delays in obtaining, or failure to obtain, approvals and permits for the building plan of the company proposed manufacturing facility.
- The Company is yet to place orders for all the plant & machineries for its proposed object, as specified in the Objects of the Issue. Any delay in placing orders, procurement of plant & machineries may delay the company implementation schedule and may also lead to increase in price of these plant & machineries, further affecting its revenue and profitability.
- There is outstanding legal proceedings involving the company Promoters and Directors. Any adverse decision in such proceedings may have a material adverse effect on its business, results of operations and financial condition.
- The company contingent liabilities as stated in its Restated Financial Statements could adversely affect the company financial conditions.
- The company Group Company have incurred losses during the last three financial years.
- The Company may not has complied with certain statutory provisions of the Companies Act, 2013. Such non- compliances / lapses may attract penalties and prosecution against the Company and its directors which could impact on the financial position of the Company to that extent.
- If any of the company products cause or is perceived to cause, side effects, the company business, results of operations and financial condition could be adversely affected.
- The company insurance coverage in connection with its business may not be adequate and may adversely affect the company operations and profitability.
- The Company operates under several statutory and regulatory permits, licenses and approvals. Its failures to obtain and/or renew any approvals or licenses in future may have an adverse impact on the company business operations.
- The Company has made certain delayed filings with respect to provisions of the GST Act, Income Tax Act, and other applicable laws in the last 5 Years.
- The Company's operations and descisions is subject to lender's strict covenants and conditions
- The Company operates under several statutory and regulatory permits, licenses and approvals. Its failures to obtain and/or renew any approvals or licenses in future may have an adverse impact on the company business operations.
- If the company fail to maintain an effective system of internal controls, its may not be able to successfully manage or accurately report the company financial risk.
- The average cost of acquisition of Equity Shares by the company Promoter could be lower than the Issue Price.
- The interests of the company Promoters and Directors may cause conflicts of interest in the ordinary course of its business.
- The company could be harmed by employee misconduct or errors that are difficult to detect and any such incidences could adversely affect its financial condition, results of operations and reputation.
- The Offer for Sale proceeds not to be available to the Company
- The Company has obtained unsecured loans amounting to Rs. 1,147.17 Lakhs on the basis of restated consolidated financial statements that may be recalled by the lenders at any time.
- The company is dependent on suppliers of raw materials required for its manufacturing operations. Absence of long-term contracts or agreements with suppliers could adversely affect the company business, financial condition and results of operations.
- Changes in laws applicable regulations governing the import of raw materials may adversely affect the company business, financial condition, and results of operations
- Risk from of data leaks in the last three years and its impact.
- Foreign currency exposure and exchange rate fluctuations between the Indian Rupee and foreign currencies
- The company business and operation is subject to extensive regulation in India, and any adverse changes in regulatory framework may affect its Business and operations.
- The risk of theft, accidents at the plant and goods in transit
- The Company has entered into certain related party transactions in the past and may continue to does so in the future.
- The company business relies on skilled personnel, and its inability to recruit and retain such personnel could adversely impact the company operations and growth prospects
- The company is dependent on its Promoters, the company senior management and other key personnel, and the loss of, or its inability to attract or retain, such persons could affect the company business, results of operations, financial condition and cash flows.
- If its fail to maintain an effective system of internal controls, the company may not be able to successfully manage or accurately report its financial risk.
- Some of the company's Board of Directors does not has experience of listed companies.
- The interests of the company Promoters and Directors may cause conflicts of interest in the ordinary course of its business.
- The company could be harmed by employee misconduct or errors that is difficult to detect and any such incidences could adversely affect its financial condition, results of operations and reputation.
- The company faces competition in its business from organized and unorganized players, which may adversely affect the company business operation and financial condition.
- Information relating to the installed manufacturing capacity, actual production and capacity utilization of the company manufacturing units included in this Red Herring Prospectus is based on various assumptions and estimates, and future production and capacity may vary.
- The company inability to manage growth could disrupt its business and reduces profitability.
- The Company's future funding requirements, in the form of further issue of capital or other securities and/or loans that might be availed by its, may turn out to be prejudicial to the interest of the shareholders depending upon the terms and conditions on which they are raised.
- In addition to normal remuneration or benefits and reimbursement of expenses, some of the company Promoters and Directors are interested in its Company to the extent of their shareholding and dividend entitlement in the Company.
- The company ability to pay dividends in the future will depends on its earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of the company financing arrangements.
- Certain key performance indicators for certain listed industry peers included in this Red Herring Prospectus has been sourced from public sources and there is no assurance that such financial and other industry information is complete.
- This Red Herring Prospectus contains information from third parties, including an industry report prepared by an independent third-party research agency, Infomerics Analytics and Research Private Limited, which the company has commissioned and paid for purposes of confirming its understanding of the industry exclusively in connection with the Offer.
- The company will continue to be controlled by its Promoter and Promoter Group after the completion of the Issue, which will allow them to influence the outcome of matters submitted for approval of the company shareholders.
- There is certain restrictions on daily movements in the price of Equity Shares, which may adversely affect a shareholder's ability to sell, or the price at which it can sell, Equity Shares at a particular point in time.
- After this Issue, the price of the Equity Shares may be highly volatile, or an active trading market for the Equity Shares may not develop.
- Market price of the company share will be decided by market forces and issue price of equity share may not be indicative of the market price its share price after the issue.
- Rights of shareholders under Indian law may be more limited than under the laws of other jurisdictions.
- Any variation in the utilization of the Net Proceeds as disclosed in this Draft Red Herring Prospectus shall be subject to certain compliance requirements, including prior approval of the shareholders of the Company.
- Equity Shares of the Company has never been publicly traded, and after the Issue, the Equity Shares may be subject to price and volume fluctuations, and an active trading market for the Equity Shares may or may not develop. Further, the Issue Price may not be indicative of the market price of the Equity Shares after the Issue.
- Investors will not be able to sell immediately on an Indian stock exchange any of the Equity Shares they purchase in the Issue.
- Holders of Equity Shares may be restricted in their ability to exercise pre-emptive rights under Indian law and thereby may suffer future dilution of their ownership position.
- A third-party could be prevented from acquiring control of the company post this Issue, because of anti-takeover provisions under Indian law.
- QIB and Non-Institutional Investors is not permitted to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid.
The Issue type of Bio Medica Laboratories Ltd is Book Building - SME.
The minimum application for shares of Bio Medica Laboratories Ltd is 2000.
The total shares issue of Bio Medica Laboratories Ltd is 3772000.
Initial public offering of up to 37,72,000 equity shares of Rs.10/- each ("Equity Shares") of Bio Medica Laboratories Limited ("Bio Medica" or "BMLL" or the "Company" or the "Issuer) for cash at a price of Rs. 139 per equity share (the "Issue Price"), aggregating to Rs. 52.43 Crores ("the Issue") comprising a fresh issue of up to 33,95,000 equity shares aggregating to Rs. 47.19 Crores by the company ("Fresh Issue") and an offer for sale of up to 1,88,500 equity shares by Mukesh Mehta and up to 1,88,500 equity shares by Pradeep Mehta ("the Promoter" or "the Selling Shareholder") aggregating to Rs. 2.62 Crores ("Offer for Sale"). Out of the issue, 1,89,000 equity shares aggregating to Rs. 2.63 Crores will be reserved for subscription by market maker ("Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. Issue of 35,83,000 equity shares of face value of Rs. 10/- each at an issue price of Rs. 139 per equity share aggregating to Rs. 49.80 Crores is hereinafter referred to as the "Net Issue". The issue and the net issue will constitute 30.00% and 28.49%, respectively of the post issue paid up equity share capital of the company.
Price Band: Rs. 139/- per equity share of face value Rs. 10/- each.
The floor price is 13.90 times the face value of equity shares.
Bids can be made for a minimum of 2,000 equity shares and in multiples of 1,000 equity shares thereafter.